wam.ae
Emirates Drug Establishment approves new indications for 'Guselkumab' for treating patients with Crohn’s disease
1 min read
•
Why This Matters
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Guselkumab, IL-23 inhibitor, and Medications. We do not yet have enough reliable article text to summarize the details.
Who Should Pay Attention
This may be most useful for Adult patients following Crohn's disease, Guselkumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Crohn's disease, Guselkumab, IL-23 inhibitor, and Medications. Use the original source link for the full details.
Keep In Mind
The original article from wam.ae has the full details, including any study limitations or source context.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Read Original Article
Originally published Apr 16, 2025, 5:52 AM